马赛替尼|T2609|TargetMol

Masitinib
790299-79-5

￥198 5mg 起订

￥327 10mg 起订

￥586 25mg 起订

上海更新日期：2024-09-23

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 马赛替尼

英文名称：: Masitinib

CAS号：: 790299-79-5

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.91%

产品类别：: 抑制剂

货号：: T2609

Product Introduction

Bioactivity

Name	Masitinib
Description	Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
Cell Research	For the assay of Ba/F3 cell proliferation, microtitre plates are seeded with a total of 104 cells/well in 100 μL of RPMI 1640 medium with 10% foetal bovine serum at 37 °C. These are supplemented, or not, with either 0.1% conditioned medium from X63-IL-3 cells or 250 ng/mL murine SCF. The murine SCF, which activates Kit, is purified from the conditioned medium of SCF-producing CHO cells. Cells are grown for 48 hours at 37 °C with Masitinib and then incubated with 10 μL/well of WST-1 reagent for 3 hours at 37 °C. The amount of formazan dye formed is quantified by its absorbance at 450 nm using a scanning multiwell spectrophotometer. A blank well without cells is used as a background control for the spectrophotometer. (Only for Reference)
Kinase Assay	In vitro enzyme-linked immunoassay with recombinant protein kinases: A 96-well microtitre plateis coated overnight with 0.25?mg/ml poly(Glu,Tyr 4:1), rinsed twice with 250?μL of washing buffer (10 mM phosphate-buffered saline [pH?7.4] and 0.05% Tween?20) and dried for 2 hours at room temperature. Assays are performed at room temperature with a final volume of 50?μL in kinase buffer (10 mM?MgCl2, 1 mM MnCl2, 1 mM sodium orthovanadate, 20 mM HEPES, pH?7.8) containing ATP at a concentration of at least twice the Km for each enzyme and an appropriate amount of recombinant enzyme to ensure a linear reaction rate. Reactions are initiated upon introduction of the enzyme and terminated with the addition of one reaction volume (50 μL) of 100?mM EDTA per 5?M urea mix. Plates are washed three times and incubated with 1:30,000 horseradish peroxidase-conjugated anti-phosphotyrosine monoclonal antibody, then washed three times and incubated with tetramethylbenzidine. The final reaction product is quantified by spectrophotometry at 450?nm.
In vitro	与安慰剂相比,Masitinib（12.5 mg/kg/d PO）可增加狗的总体TTP（肿瘤进展时间）.在表达Δ27的Ba/F3 移植瘤模型中,30 mg/kg Masitinib抑制肿瘤生长和提高平均存活时间,没有心脏毒性或遗传毒性.Masitinib和吉西他滨联用表现出对抗吉西他滨的细胞系Mia Paca2和Panc1增殖的协同抑制作用.
In vivo	Masitinib抑制表达人类野生型KIT的Ba/F3的细胞中干细胞因子诱导的细胞增殖,IC50为150 nM,而抑制IL-3刺激的增殖时,IC50值约>10 μM。Masitinib在表达PDGFR-α的Ba/F3细胞中,抑制PDGF-BB刺激的增殖和 PDGFR-α 酪氨酸磷酸化作用,IC50为300 nM。Masitinib浓度≤500 nM时为ATP竞争性抑制剂。Masitinib也有效抑制重组PDGFR和胞内激酶Lyn及FGFR 3。然而,Masitinib对ABL和c-Fms抑制效果很弱。在哺乳动物细胞系和BMMC中,马西替尼还能抑制SCF刺激的人Kit酪氨酸磷酸化。Masitinib抑制Ba/F3细胞中KIT获得的功能突变,包括V559D突变和Δ27鼠突变,IC50分别为3和5 nM。在两种新型ISS细胞系中,Masitinib抑制细胞生长和PDGFR磷酸化,这表明Masitinib显示针对原发性和转移性ISS细胞系的活性,并可能有助于ISS的临床管理。Masitinib对脱颗粒,细胞因子产生和骨髓肥大细胞迁移的抑制效果比imatinib强很多。Masitinib抑制肥大细胞瘤细胞系包括 HMC-1α155和FMA3的细胞增殖,IC50分别为10和30 nM。
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 60 mg/mL (120.33 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 4 mg/mL (8.02 mM)
Keywords	PTK2 \| SCFR \| PDGFR \| Src \| inhibit \| c-Kit \| Apoptosis \| CD117 \| Focal adhesion kinase \| PTK2 protein tyrosine kinase 2 \| AB-1010 \| FAK \| FGFR \| Inhibitor \| Platelet-derived growth factor receptor \| Fibroblast growth factor receptor \| Masitinib \| AB 1010
Inhibitors Related	Metronidazole \| Ferulic Acid \| 5-Fluorouracil \| Stavudine \| Tributyrin \| Dextran sulfate sodium salt (MW 4500-5500) \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Sodium 4-phenylbutyrate
Related Compound Libraries	Inhibitor Library \| Bioactive Compound Library \| Anti-Cancer Approved Drug Library \| Anti-Cancer Active Compound Library \| Kinase Inhibitor Library \| Membrane Protein-targeted Compound Library \| Anti-Neurodegenerative Disease Compound Library \| Drug Repurposing Compound Library \| Anti-Cancer Clinical Compound Library \| Anti-Cancer Drug Library

马赛替尼|||SB-75 diacetate|||AB1010|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子